Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polymerase delta-interacting protein 3 (POLDIP3)
- Target
- POLDIP3
- Molecular classification
- DNA replication accessory protein, RNA recognition motif-containing (RRM) protein, mRNA processing factor, Protein-protein interaction scaffold, Other (not an enzyme, receptor, transporter, ion channel, or transcription factor)
01
Overview
Polymerase delta-interacting protein 3 (POLDIP3) is a multifunctional nuclear protein that serves as an accessory factor in DNA replication and RNA processing. It directly interacts with the DNA polymerase delta complex and proliferating cell nuclear antigen (PCNA) to promote DNA replication, particularly under conditions of replication stress. POLDIP3 is required for the activation and maintenance of DNA damage checkpoints, safeguarding genome integrity and participating in the repair and restart of stalled replication forks. Additionally, the protein contains an RNA recognition motif, facilitating roles in mRNA translation and export, through interaction with ribosomal protein S6 kinase 1 (S6K1) and ALY/REF-like complexes. POLDIP3 is widely expressed and its dysregulation is implicated in cancer development due to its roles in genomic stability and cell cycle control.
- Other names
- POLDIP3PDIP3PDIP46SKARKIAA1649Polymerase delta-interacting protein 346 kDa DNA polymerase delta interaction proteinS6K1 Aly/REF-like targetRNA-binding protein p46
02
Mechanism of action
Not applicable. No drugs are known to directly target POLDIP3.
03
Biological functions
DNA replication (regulation and stabilization of DNA polymerase delta activity)Genome stability maintenanceRegulation of cell growth and proliferationmRNA translation efficiency and exportRNA binding and processingCheckpoint activation and DNA damage response
04
Disease associations
Cancer (via regulation of genome stability and cell proliferation)Cardiomyopathy (as reported in genomic studies)Other (implicated generally in diseases related to replication stress and genome instability)
05
Safety considerations
None reported for targeted therapy. Potential therapeutic challenges would theoretically involve effects on genome stability, cell growth, and mRNA processing, but this is speculative as no POLDIP3-directed therapies are in use.
06
Biomarkers
No clinically validated biomarkers for patient selection or efficacy monitoring related to POLDIP3 are documented. Changes in expression or mutation status may have research value for cancer and genome stability but are not in clinical use.
Beyond the preview
Go deeper on Polymerase delta-interacting protein 3 (POLDIP3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polymerase delta-interacting protein 3 (POLDIP3).